Skip to content
Toggle Navigation
Home
Science
Team
News
Contact
Search for:
News
News
MBQ Pharma announces the First-in-Human Dose of MBQ-167 for Advanced Breast Cancer in a Phase 1 Clinical Trial in Puerto Rico with the dual targeted Rac/Cdc42 inhibitor
Page load link
Go to Top